DLBCL

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses long-term findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory aggressive non-Hodgkin lymphoma.

Treatment with the CD19-targeted chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel, formally known as JCAR017) demonstrated a complete response rate of 63% and an objective response rate of 81% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Lymphoma expert Andrew M. Evens, DO, MSc, FACP, has joined Rutgers Cancer Institute of New Jersey as associate director. He is also serving as medical director of the oncology service line at RWJBarnabas Health. Evens will focus on integrated cancer care delivery in his roles across both institutions.

Peter Martin, MD, discusses a phase I, open-label, multicenter trial of oral azacitidine (Vidaza) plus R-CHOP in people with high-risk, previously untreated DLBCL, grade 3B follicular lymphoma, or transformed lymphoma.

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.

Based on results of the phase II JULIET study, a supplemental biologics license application for the CAR T-cell therapy tisagenlecleucel (Kymriah) has been granted a priority review by the FDA as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for or relapse after autologous stem cell transplant.

Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with Hodgkin lymphoma in a phase I study of patients with B-lymphoid malignancies; among patients with B-cell non-Hodgkin lymphoma treated with the monotherapy, the overall response rate was 11.1%, according to a poster presentation at the 2017 ASH Annual Meeting. 

Treatment with tisagenlecleucel (Kymriah) continues to excite the possibilities seen with chimeric antigen receptor T-cell therapy with impressive responses seen with the therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. In the phase II JULIET trial, an overall response rate of 53.1% was observed, according to findings presented at the ASH Annual Meeting. 

Pembrolizumab (Keytruda) has received a priority review from the FDA for a supplemental biologics license application (sBLA) for the treatment of adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL), according to a press release from Merck, the manufacturer of pembrolizumab. The findings were first presented at the 14th International Conference on Malignant Lymphoma and updated data were recently presented at the 2017 ASH Annual Meeting.

Updated results from the TRANSCEND study demonstrated that liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an 81% objective response rate and a 63% complete remission rate in patients with relapsed/refractory diffuse large B-cell lymphoma.

The addition of brentuximab vedotin (Adcetris) to doxorubicin, vinblastine, and dacarbazine (A+AVD) reduced the risk of progression and death by 23% in patients with advanced-stage Hodgkin lymphoma (HL) compared with standard ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) chemotherapy, according to results of the phase III ECHELON-1 clinical trial. 

Mogamulizumab improved progression-free survival in previously treated patients with cutaneous T-cell lymphoma by 4.6 months compared with vorinostat (Zolinza), according to findings from the phase III MAVORIC study.

A biologics license application for mogamulizumab has been granted a priority review by the FDA for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy, Kyowa Hakko Kirin, the manufacturer of the anti-CCR4 monoclonal antibody, has announced.

Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma.

Martin Dreyling, MD, discusses results of the phase II CHRONOS-1 study in patients with relapsed or refractory indolent B-cell lymphoma.

Pembrolizumab has been approved by the European Commission for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Tisagenlecleucel-T has been granted a breakthrough therapy designation by the FDA for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel has shown promising results in patients with diffuse large B-cell lymphoma, primary mediastinal lymphoma, and transformed follicular lymphoma, according to findings presented at the 2017 AACR Annual Meeting.

A majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib, according to results from the phase II CHRONOS-1 trial.<br /> &nbsp;

A biologics license application has been submitted for axicabtagene ciloleucel (KTE-C19) as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Patients with lymphoma who are treated with brentuximab vedotin often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with brentuximab vedotin outweigh the risk of neuropathy.&nbsp;

A review of various frontline treatment options in follicular lymphoma and an outline of an algorithm for approaching patients with newly diagnosed follicular lymphoma.

Nathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.

Michelle Fanale, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses patient selection for newly approved agents in T-cell lymphoma.

Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3&zeta;/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.